# Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

> **NCT04037254** · PHASE1,PHASE2 · COMPLETED · sponsor: **NRG Oncology** · enrollment: 22 (actual)

## Conditions studied

- Prostate Adenocarcinoma
- Stage IIC Prostate Cancer AJCC v8
- Stage III Prostate Cancer AJCC v8
- Stage IIIA Prostate Cancer AJCC v8
- Stage IIIB Prostate Cancer AJCC v8
- Stage IIIC Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Gonadotrophin Releasing Hormone
- **RADIATION:** Intensity-Modulated Radiation Therapy
- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT04037254
- **Lead sponsor:** NRG Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-08
- **Primary completion:** 2024-07-01
- **Final completion:** 2025-12-23
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04037254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04037254, "Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04037254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*